FDBK.L

Feedback Plc
Feedback PLC - CDC Contract Awarded by Queen Victoria Hospital
1st July 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4616U
Feedback PLC
01 July 2024
 

Feedback plc

 

Feedback Wins CDC Contract With Queen Victoria Hospital

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, is pleased to announce that it has been awarded a contract by Queen Victoria Hospital NHS Foundation Trust ("QVH") to provide its Bleepa Community Diagnostics Centre ("CDC") solution.

 

This contract, which is worth £495,000 for an initial 12-month term with the ability to extend by another 12 months, has been awarded to Feedback as the successful bidder in a procurement process launched by QVH in November 2023, to provide a digital infrastructure to facilitate patient specific pathways through the CDC, linking both primary and secondary care settings.  

 

Feedback has already delivered cost and time savings at QVH initially through its pilot programme. The pilot has provided a substantial reduction in wait time compared to the national 18-week referral-to-treatment (RTT) target, without the need for additional clinical staff. This contract award provides the opportunity for Feedback to continue to deliver the core digital infrastructure required for the CDCs to reduce the elective care backlog and deliver a programme for the maximum benefit of staff, patients and the wider NHS. The success of Bleepa at QVH provides a valuable case study for the wider market across the UK.

 

Dr Tom Oakley, CEO Feedback plc said:

 

"We are extremely pleased to announce that after two years of piloting our CDC solution with QVH we have been awarded a contract for the Bleepa platform. This contract will allow us to now expand the service offering to multiple GP practices and move beyond the breathlessness pathway to look at other specialty areas.

 

"This contract award is a compelling validation of our technology. QVH is an example that speaks to the rest of the NHS and is the pioneer of the symptom-based pathway on Bleepa, an approach which has demonstrated huge potential to cut wait times and improve care for patients. This contract will give others the confidence to progress with this care model and our platform, allowing us to now move forward to capture both the regional and national opportunity in front of us and ultimately to bring better, faster care to patients across the UK."

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 


Panmure Liberum Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley/Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 


Walbrook PR Ltd;

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Nick Rome/Joe Walker

07748 325 236 or 07407 020 470

 

 

About Feedback

 

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment, with greater connectivity across organisations.

 

Our products Bleepa® and CareLocker® work together to deliver unparalleled value to our customers. Bleepa® is our application layer and sits on top of CareLocker® as our data layer. Bleepa® is a clinician facing platform that displays clinical results from a patient's CareLocker® at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker® data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.  

 

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTEAXKPAFSLEFA]]>
TwitterFacebookLinkedIn